Does Relapsing-Remitting MS Reduce Life Expectancy?
At a Glance
Relapsing-remitting MS does not determine a fixed lifespan. Historical averages combine all MS types and older care, while today’s outlook depends on disease activity, overall health, treatment, smoking, infection prevention, fall safety, cardiovascular care, and mental health.
In this answer
3 sections
Yes, studies of historical populations show that having multiple sclerosis (MS) can reduce average life expectancy, but being diagnosed with relapsing-remitting multiple sclerosis (RRMS) does not mean you cannot live a long, full life. A major review of historical MS data estimated that the condition is associated with a lifespan reduction of about 7.5 years, with the average life expectancy for someone with MS being around 75.9 years compared to 83.4 years in the general population [1].
However, it is vital to understand that this is a historical average for all forms of MS combined, including progressive types and eras before modern medical care. It is not a specific forecast for someone living with RRMS today. Life expectancy for people with MS has been steadily improving over recent decades [2]. Long-term survival depends heavily on your specific disease activity, age, overall health, access to care, and the steps you and your medical team take to prevent complications.
Urgent Safety Warning
Seek immediate medical attention if you experience:
- Thoughts of self-harm or suicide: Contact local emergency services, go to the nearest emergency department, or call a crisis line immediately. Do not wait for a routine appointment.
- Severe infection signs: High fever, severe flank pain, confusion, shortness of breath, or repeated choking with meals.
- Serious falls: Any fall resulting in a head injury, severe pain, or inability to move.
The Impact of Modern Treatments
The landscape of MS care has changed dramatically. Disease-modifying therapies (DMTs) are proven to reduce inflammatory disease activity, prevent relapses, and reduce new MRI lesions. While clinical trials for these drugs focus on short-term outcomes, long-term observational research associates consistent DMT use with lower mortality rates [3][4].
It is important to note that these are observational associations. Patients who consistently take DMTs might also have better overall access to healthcare or fewer other illnesses, so the medications alone do not guarantee a longer life. The improved survival rates seen in recent decades also reflect earlier diagnoses and better general medical care [2]. Never stop or change your DMT without discussing it with your neurologist, as doing so can risk a rebound in MS activity.
Important and Treatable Risk Factors
While population averages cannot predict your individual future, certain complications are associated with a higher mortality risk in MS. Many of these are preventable or manageable.
Infections
In historical data for all MS types, the relative risk of dying from an infection was nearly three times higher than in the general public [5]. However, this risk is not uniform; it is highest for those with advanced disability, swallowing problems, or specific medication risks.
- Respiratory infections: Clinically important swallowing difficulties (dysphagia) can cause food or liquid to enter the lungs (aspiration), leading to severe pneumonia [6][7]. If you notice coughing or choking with meals, a wet-sounding voice, or unexplained weight loss, ask for a speech-and-swallow evaluation.
- Urinary tract infections (UTIs): Bladder dysfunction is common. However, urgency or incontinence can happen without an infection, and a positive urine test without symptoms often does not require antibiotics. Seek evaluation if you develop new symptoms like fever, flank/back pain, vomiting, or confusion, which can signal a serious systemic infection (an infection that spreads throughout the body) [6][8].
Falls and Physical Injuries
Falls are highly prevalent in MS, but the risk depends on your level of disability, fatigue, and vision or gait problems [9][10]. Fall risk increases significantly if you take multiple medications, particularly sedatives or muscle relaxants [10][11]. Do not taper or stop these medications on your own, as abrupt changes can cause dangerous withdrawal symptoms. Instead, ask your doctor or pharmacist for a medication review. Physical therapy, balance training, and home-safety adjustments can also reduce your risk.
Smoking
Smoking is an important, modifiable risk associated with worse MS and general-health outcomes. In observational studies, current smoking was associated with double the risk of all-cause mortality in people with MS [7]. Smoking is also associated with a faster transition from RRMS to secondary progressive MS (SPMS), a phase of steady disability worsening [12][13]. Quitting can improve your prognosis, and your doctor can provide practical cessation support, such as counseling or nicotine replacement.
Cardiovascular Disease
People with MS have a higher rate of cardiovascular mortality than the general population [5]. In addition to the general health risks, vascular risk factors like high blood pressure, diabetes, and heart disease are associated with greater brain volume loss (atrophy) and higher MS lesion burdens in some studies [14]. Managing your blood pressure, cholesterol, and blood sugar is essential for both your heart and your brain.
Depression and Mental Health
Depression is common in MS and is associated with a lower quality of life [15]. It is influenced by biology, stress, and sometimes medications. The combination of MS and depression synergistically increases mortality risk [16], and historical studies show the relative risk of suicide among people with MS is more than twice that of the general population [5]. Depression is a highly treatable condition. Routine screening and prompt individualized care are vital for your long-term well-being.
Medication Complications
While DMTs protect the central nervous system, they can alter the immune system. Risks vary substantially by medication, treatment history, and your baseline immune status. Depending on the drug, risks can include specific viral infections, cardiovascular issues like high blood pressure [17], or rare brain infections like progressive multifocal leukoencephalopathy (PML) [18]. Your prescribing team will tailor a specific laboratory and infection-monitoring plan to your medication to ensure its benefits continue to outweigh the risks.
Routine Primary and Specialty Care
A long, full life with RRMS requires whole-person care. Build a care team that includes a primary care doctor for routine wellness visits, age-appropriate cancer screenings, blood pressure and lipid management, and medication reviews. Communicating openly about your symptoms—whether they are physical or emotional—ensures you get the proactive, individualized care you need.
Common questions in this guide
Does RRMS always shorten your life expectancy?
What determines how long someone with RRMS may live?
Can MS disease-modifying therapies help people with RRMS live longer?
What MS complications can affect survival?
Does smoking make the outlook for RRMS worse?
When should a person with RRMS seek urgent medical help?
Can RRMS become secondary progressive MS?
Related questions
Show more
Get notified when new evidence is published on relapsing-remitting multiple sclerosis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (18)
- 1
Diagnosis and Treatment of Multiple Sclerosis: A Review.
McGinley MP, Goldschmidt CH, Rae-Grant AD
JAMA 2021; (325(8)):765-779 doi:10.1001/jama.2020.26858.
PMID: 33620411 - 2
Excess mortality among patients with multiple sclerosis in Denmark has dropped significantly over the past six decades: a population based study.
Koch-Henriksen N, Laursen B, Stenager E, Magyari M
Journal of neurology, neurosurgery, and psychiatry 2017; (88(8)):626-631 doi:10.1136/jnnp-2017-315907.
PMID: 28705951 - 3
Multiple sclerosis: effect of beta interferon treatment on survival.
Kingwell E, Leray E, Zhu F, et al.
Brain : a journal of neurology 2019; (142(5)):1324-1333 doi:10.1093/brain/awz055.
PMID: 30883636 - 4
Impact of Adherence with Disease-Modifying Therapies on All-Cause Mortality Rates Among Veterans with Multiple Sclerosis.
Rabadi MH, Just K, Xu C
Medical science monitor : international medical journal of experimental and clinical research 2022; (28()):e938116 doi:10.12659/MSM.938116.
PMID: 36131525 - 5
Mortality in multiple sclerosis: meta-analysis of standardised mortality ratios.
Manouchehrinia A, Tanasescu R, Tench CR, Constantinescu CS
Journal of neurology, neurosurgery, and psychiatry 2016; (87(3)):324-31 doi:10.1136/jnnp-2015-310361.
PMID: 25935887 - 6
Multiple cause of death analysis in multiple sclerosis: A population-based study.
Harding K, Zhu F, Alotaibi M, et al.
Neurology 2020; (94(8)):e820-e829 doi:10.1212/WNL.0000000000008907.
PMID: 31932517 - 7
Epidemiology of multiple sclerosis: results from a large observational study in the UK.
Jick SS, Li L, Falcone GJ, et al.
Journal of neurology 2015; (262(9)):2033-41 doi:10.1007/s00415-015-7796-2.
PMID: 26067217 - 8
Standardized mortality ratios in multiple sclerosis: Systematic review with meta-analysis.
Smyrke N, Dunn N, Murley C, Mason D
Acta neurologica Scandinavica 2022; (145(3)):360-370 doi:10.1111/ane.13559.
PMID: 34820847 - 9
Nationwide Update on Prevalence of Falls, Injurious Falls, Concerns About Falling, and Fall Prevention in Persons With Multiple Sclerosis.
Abou L, McCloskey C, Wernimont C, et al.
American journal of physical medicine & rehabilitation 2024; (103(9)):811-818 doi:10.1097/PHM.0000000000002454.
PMID: 38466198 - 10
Medications Are Associated with Falls in People with Multiple Sclerosis: A Prospective Cohort Study.
Cameron MH, Karstens L, Hoang P, et al.
International journal of MS care 2015; (17(5)):207-14 doi:10.7224/1537-2073.2014-076.
PMID: 26472941 - 11
Polypharmacy in Multiple Sclerosis: Prevalence, Risks, and Mitigation Strategies.
Chapman WD, Herink MC, Cameron MH, Bourdette D
Current neurology and neuroscience reports 2023; (23(9)):521-529 doi:10.1007/s11910-023-01289-9.
PMID: 37523105 - 12
Effect of Smoking Cessation on Multiple Sclerosis Prognosis.
Ramanujam R, Hedström AK, Manouchehrinia A, et al.
JAMA neurology 2015; (72(10)):1117-23 doi:10.1001/jamaneurol.2015.1788.
PMID: 26348720 - 13
Early predictors of conversion to secondary progressive multiple sclerosis.
Barzegar M, Najdaghi S, Afshari-Safavi A, et al.
Multiple sclerosis and related disorders 2021; (54()):103115 doi:10.1016/j.msard.2021.103115.
PMID: 34216997 - 14
Cardiovascular risk factors are associated with increased lesion burden and brain atrophy in multiple sclerosis.
Kappus N, Weinstock-Guttman B, Hagemeier J, et al.
Journal of neurology, neurosurgery, and psychiatry 2016; (87(2)):181-7 doi:10.1136/jnnp-2014-310051.
PMID: 25722366 - 15
Psychosocial and Medical Determinants of Health-related Quality of Life in Patients with Relapsing-Remitting Multiple Sclerosis.
Boogar IR, Talepasand S, Jabari M
Noro psikiyatri arsivi 2018; (55(1)):29-35 doi:10.29399/npa.16983.
PMID: 30042638 - 16
Interface of Multiple Sclerosis, Depression, Vascular Disease, and Mortality: A Population-Based Matched Cohort Study.
Palladino R, Chataway J, Majeed A, Marrie RA
Neurology 2021; (97(13)):e1322-e1333 doi:10.1212/WNL.0000000000012610.
PMID: 34470802 - 17
Risk of cardiovascular disease in patients with multiple sclerosis treated with fingolimod compared to natalizumab: A nationwide cohort study of 2095 patients in Denmark.
Framke E, Thygesen LC, Malmborg M, et al.
Multiple sclerosis (Houndmills, Basingstoke, England) 2024; (30(2)):184-191 doi:10.1177/13524585231221415.
PMID: 38205784 - 18
Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
Rae-Grant A, Day GS, Marrie RA, et al.
Neurology 2018; (90(17)):777-788 doi:10.1212/WNL.0000000000005347.
PMID: 29686116
This page is for informational purposes only and does not constitute medical advice or predict your individual life expectancy. Discuss your RRMS outlook, treatment safety, and warning signs with your neurologist and primary care clinician.